Upper airways in aspirin-exacerbated respiratory disease

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 1, 2015, Pages 21-26

  Choi, Jeong Hee ^a   Kim, Ji Hye ^b   Park, Hae Sim ^b  

^a Hallym University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Aspirin hypersensitivity; asthma; chronic rhinosinusitis; desensitization; nasal polyp

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN E2; STAPHYLOCOCCUS ENTEROTOXIN; TRANSCRIPTION FACTOR RUNX2; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; ISOMERASE; POSTN PROTEIN, HUMAN; PROSTAGLANDIN E SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; CD4+ T LYMPHOCYTE; CELL MATURATION; CHRONIC RHINOSINUSITIS; CYTOKINE RELEASE; DESENSITIZATION; ENDOSCOPIC SINUS SURGERY; EOSINOPHIL; GRANULOCYTE; HUMAN; INFLAMMATORY CELL; LEUKOCYTE; NOSE POLYP; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ADHESION; ANIMAL; ASTHMA, ASPIRIN-INDUCED; BLOOD; CHRONIC DISEASE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; RHINITIS; SINUSITIS;

ANIMALS; ASTHMA, ASPIRIN-INDUCED; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHRONIC DISEASE; DESENSITIZATION, IMMUNOLOGIC; DINOPROSTONE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICE, KNOCKOUT; RHINITIS; SINUSITIS;

EID: 84920834058     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000122     Document Type: Review

References (52)

1. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3-10.
2. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432-436.
3. Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 2013; 33:163-176.
4. Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2014; 133:286-287.e1-9.
5. Graefe H, Roebke C, Schäfer D, et al. Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination. J Allergy 2012; 2012:1-10.
6. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-478.
7. Mascia K, Borish L, Patrie J, et al. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005; 94:652-657.
8. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Aller gy Asthma Immunol Res 2014; 6:288-295.
9. Perez-Novo CA, Watelet JB, Claeys C, et al. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005; 115:1189-1196.
10. Higashi N, Taniguchi M, Mita H, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004; 113:277-283.
11. Adamusiak AM, Stasikowska-Kanicka O, Lewandowska-Polak A, et al. Expression of arachidonate metabolism enzymes and receptors in nasal polyps of aspirin-hypersensitive asthmatics. Int Arch Allergy Immunol 2011; 157:354-362.
12. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493-1499.
13. Corrigan C, Mallett K, Ying S, et al. Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005; 115:316-322.
14. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-11617.
15. Roca-Ferrer J, Garcia-Garcia FJ, Pereda J, et al. Reduced expression of COXsand production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J Allergy Clin Immunol 2011; 128:66-72.
16. Liu T, Laidlaw TM, Feng C, et al. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci 2013; 110:16987-16992.
17. Laidlaw TM, Cutler AJ, Kidder MS, et al. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2014; 133:1692-1701.
18. Choi GS, Kim JH, Shin YS, et al. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. Clin Exp Allergy 2013; 43:730-740.
19. Steinke JW, Liu L, Huyett P, et al. Prominent role of IFN-7 in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2013; 132:856-865.
20. Steinke JW, Negri J, Liu L, et al. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 2014; 193:41-47.
21. Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119:3790-3798.
22. Bachert C, Zhang N. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'. J Intern Med 2012; 272:133-143.
23. Seiberling KA, Conley DB, Tripathi A, et al. Superantigens and chronic rhinosinusitis: detection of staphylococcal exotoxins in nasal polyps. Laryngoscope 2005; 115:1580-1585.
24. Suh Y, Yoon S, Sampson A, et al. Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma. Clin Exp Allergy 2004; 34:1270-1275.
25. Perez-Novo CA, Kowalski ML, Kuna P, et al. Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship. Int Arch Allergy Immunol 2004; 133:255-260.
26. Conley DB, Tripathi A, Seiberling KA, et al. Superantigens and chronic rhinosinusitis: skewing of T-cell receptor Vp-distributions in polyp-derived CD4+ and CD8+ T cells. Am J Rhinol 2006; 20:534-539.
27. Bachert C, Van Steen K, Zhang N, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol 2012; 130:376-381.
28. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-1118.
29. Miller B, Mirakian R, Gane S, et al. Nasal lysine aspirin challenge in the diagnosis of aspirin: exacerbated respiratory disease: asthma and rhinitis. Clin Exp Allergy 2013; 43:874-880.
30. Hopkins C, Browne JP, Slack R, et al. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 2007; 137:555-561.
31. Park SM, Park JS, Park HS, et al. Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways. Allergy Asthma Immunol Res 2013; 5:258-276.
32. Choi JH, Lee KW, Oh HB, et al. HLA association in aspirin-intolerant asthma: DPB1 ∗0301 as a strong marker in a Korean population. J Allergy Clin Immunol 2004; 113:562-564.
33. Kim MA, Izuhara K, Ohta S, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2014; 113:314-320.
34. Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hyper-sensitivity. Allergy Asthma Immunol Res 2014; 6:156-162.
35. Wentzel JL, Soler ZM, DeYoung K, et al. Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review. Am J Rhinol 2013; 27:482-489.
36. Israel E. The protective effects of leukotriene modifiers in aspirin-induced asthma. Postgrad Med 2000; 108:40-44.
37. Dalziel K, Stein K, Round A, et al. Systematic review of endoscopic sinus surgery for nasal polyps. Health Technol Assess 2003; 7:1-159.
38. Batra PS, Kern RC, Tripathi A, et al. Outcome analysis of endoscopic sinus surgery in patients with nasal polyps and asthma. Laryngoscope 2003; 113:1703-1706.
39. Mendelsohn D, Jeremic G, Wright ED, et al. Revision rates after endoscopic sinus surgery: a recurrence analysis. Ann Otol Rhinol Laryngol 2011; 120:162-166.
40. Kim JE, Kountakis SE. The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007; 86:396-399.
41. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008; 63:1228-1234.
42. Sweet JM, Stevenson DD, Simon RA, et al. Long-term effects of aspirin desensitization-treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85:59-65.
43. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98:751-758.
44. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111:180-186.
45. Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2003; 90:338-341.
46. Kowalski M, Grzelewska-Rzymowska I, Szmidt M, et al. Clinical efficacy of aspirin in 'desensitised' aspirin-sensitive asthmatics. Eur Respir J 1986; 69:219-225.
47. Comert S, Celebioglu E, Yucel T, et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy 2013; 68:1443-1451.
48. Burnett T, Katial R, Alam R. Mechanisms of aspirin desensitization. Immunol Allergy Clin North Am 2013; 33:223-236.
49. Katial RK, Strand M, Prasertsuntarasai T, et al. The effect of aspirin desensi-tization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 2010; 126:738-744.
50. Aksu K, Kurt E, Alatas O, et al. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease. Allergy Asthma Proc 2014; 35:148-155.
51. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128:989-995.
52. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110-116.